Viatris INC
Forward trial catalysts linked to VTRS
CSA tracks 2 forward catalysts for Viatris INC across 1 asset, spanning Phase 3. The nearest is a readout expected Dec 31, 2026 (day precision). Confidence across its tracked catalysts breaks down as 2 medium. Tracked indications include Lupus Erythematosus, Systemic, Nephritis, Lupus.
VTRS in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Viatris INC has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
4 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| cenerimod | NCT05672576 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | Viatris Innovation GmbH | Lupus Erythematosus, Systemic |
| cenerimod | NCT05648500 catalyst | Phase 3 | Active, not recruiting | 2027-03-31 | Experimental | Viatris Innovation GmbH | Lupus Erythematosus, Systemic |
| cenerimod | NCT07201129 | Phase 3 | Recruiting | 2029-08 | Experimental | Viatris Innovation GmbH | Nephritis, Lupus; Lupus Erythematosus, Systemic |
| cenerimod | NCT06475742 | Phase 3 | Enrolling by invitation | 2032-09 | Experimental | Viatris Innovation GmbH | Lupus Erythematosus, Systemic |
Every trial the CSA sample links to VTRS's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →